InsiderSource
BBIO

BridgeBio Pharma, Inc.

SEC CIK 1743881
$67.55 −13.6% · 90 days
90-day buys
$0
0 open-market
90-day sells
$20.29M
46 open-market
Net insider flow
−$20.29M
Net selling
Filings shown
120
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at BBIO have sold a net $20.29M of stock (0 open-market buys vs 46 sells).

Largest recent trade: Ellis Andrea sold $4.21M of BBIO, trimming their stake 78%.

Most active filer: Kumar Neil, with 91 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for BBIO, newest first
View on SEC EDGAR ↗
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −1.3%

Kumar Neil sold $480.3K of BBIO, trimming their stake 1%.

−$480.3K
7,147 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −1.6%

Kumar Neil sold $572.7K of BBIO, trimming their stake 2%.

−$572.7K
8,437 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.8%

Kumar Neil sold $304.5K of BBIO, trimming their stake 1%.

−$304.5K
4,416 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.2%

Kumar Neil sold $480.3K of BBIO.

−$480.3K
7,148 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.2%

Kumar Neil sold $572.7K of BBIO.

−$572.7K
8,437 sh @ $68
Advertisement
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.1%

Kumar Neil sold $304.5K of BBIO.

−$304.5K
4,415 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.4%

Kumar Neil sold $144.6K of BBIO.

−$144.6K
2,200 sh @ $66
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.3%

Kumar Neil sold $95.3K of BBIO.

−$95.3K
1,429 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −2.9%

Kumar Neil sold $1.08M of BBIO, trimming their stake 3%.

−$1.08M
15,921 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.1%

Kumar Neil sold $30.7K of BBIO.

−$30.7K
450 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.1%

Kumar Neil sold $144.6K of BBIO.

−$144.6K
2,200 sh @ $66
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago

Kumar Neil sold $95.3K of BBIO.

−$95.3K
1,429 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago ΔOwn −0.4%

Kumar Neil sold $1.08M of BBIO.

−$1.08M
15,921 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 4d ago

Kumar Neil sold $30.7K of BBIO.

−$30.7K
450 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 2w ago ΔOwn −0.8%

Kumar Neil sold $152.4K of BBIO, trimming their stake 1%.

−$152.4K
2,256 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 2w ago ΔOwn −2.5%

Kumar Neil sold $459.3K of BBIO, trimming their stake 3%.

−$459.3K
6,725 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 2w ago ΔOwn −1.9%

Kumar Neil sold $351.1K of BBIO, trimming their stake 2%.

−$351.1K
5,072 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 2w ago ΔOwn −4.4%

Kumar Neil sold $792.9K of BBIO, trimming their stake 4%.

−$792.9K
11,250 sh @ $70
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed 2w ago ΔOwn −0.3%

Kumar Neil sold $56.7K of BBIO.

−$56.7K
800 sh @ $71
BBIO
BridgeBio Pharma, Inc.
Sell Trimarchi Thomas · President and CFO · Open-market sale · filed 3w ago ΔOwn −2.8%

Trimarchi Thomas sold $677.7K of BBIO, trimming their stake 3%.

−$677.7K
10,456 sh @ $65
BBIO
BridgeBio Pharma, Inc.
Sell Trimarchi Thomas · President and CFO · Open-market sale · filed 3w ago ΔOwn −0.9%

Trimarchi Thomas sold $210.7K of BBIO, trimming their stake 1%.

−$210.7K
3,195 sh @ $66
BBIO
BridgeBio Pharma, Inc.
Tax withholding Kumar Neil · Director, Chief Executive Officer · Tax withholding · filed 3w ago ΔOwn −12%
−$2.4M
36,236 sh @ $66
BBIO
BridgeBio Pharma, Inc.
Sell Scott Randal W. · Director · Open-market sale · filed 3w ago ΔOwn −29%

Scott Randal W. sold $413.5K of BBIO, trimming their stake 29%.

−$413.5K
6,200 sh @ $67
Advertisement

About BBIO insider activity

This page tracks every recent Form 4 filed for BridgeBio Pharma, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is BBIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for BridgeBio Pharma, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.